MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
2024年9月10日 - 1:00AM
ビジネスワイヤ（英語）
Article 223-16 of the General Regulations of
the Financial Markets Authority
(AMF - Autorité des Marchés Financiers)
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a
clinical-stage biotechnology company and a leader in the
development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
enhancing survival of patients with cancer, today published the
number of shares comprising the share capital and the total number
of voting rights (Article L. 233-8 of the French Commercial Code
(Code de commerce) and Article 223-16 of the General Regulations of
French Autorité des Marchés Financiers (AMF)) on August 31,
2024.
Listing place: Euronext Paris
ISIN code: FR0012634822
Website: www.maatpharma.com
Date
Total number of shares comprising
the share capital
Total number of theoretical
voting rights (1)
Total number of effective voting
rights (2)
08/31/24
13 918 583
13 918 583
13 890 384
(1) In accordance with Article 223-11 of the AMF General
Regulation, this number is calculated on the basis of all shares to
which voting rights are attached, including shares whose voting
rights have been suspended (2) Effective voting rights correspond
to the total number of voting rights that may be used at a General
Meeting. The total number of effective voting rights is calculated
without taking into account the shares with suspended voting
rights.
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma has launched, in
March 2022, an open-label, single arm Phase 3 clinical trial in
patients with acute GvHD, following the achievement of its proof of
concept in a Phase 2 trial. Its powerful discovery and analysis
platform, gutPrint®, enables the identification of novel disease
targets, evaluation of drug candidates, and identification of
biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome, in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240909961856/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50 invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com Trophic Communications Jacob VERGHESE
or Desmond JAMES +49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
過去 株価チャート
から 12 2024 まで 1 2025
Maat Pharma (EU:MAAT)
過去 株価チャート
から 1 2024 まで 1 2025
